insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Site- and Stage-Adapted Treatment Strategies for Gastrointestinal Diffuse Large B-Cell Lymphoma.

1/5 보강
European journal of haematology 2025 Vol.115(3) p. 239-250
Retraction 확인
출처
PubMed DOI

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
701 patients with DLBCL at our institution between March 2004 and June 2024, including 160 with GI-DLBCL.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In localized intestinal DLBCL, multivariate analysis identified surgery followed by chemotherapy as a favorable prognostic factor for OS (HR: 0.23; 95% CI: 0.067-0.83; p = 0.024). [CONCLUSIONS] Gastrointestinal diffuse large B-cell lymphoma had survival outcomes comparable to those of non-GI-DLBCL, suggesting site- and stage-specific therapies may confer a survival benefit.

Yagi Y, Kanemasa Y, Sasaki Y, Matsubayashi M, Yamamura Y, Fujino K, Kuga T, Kanai N, Masuda Y, Fujita K, Ishimine K, Hayashi Y, Mino M, Takahara A, Tamura T, Nakamura S, Okuya T, Matsuda S, Shimizuguchi T, Cho H, Kawai K, Shimoyama T

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

[OBJECTIVES] Although gastrointestinal diffuse large B-cell lymphoma (GI-DLBCL) is managed variously, the optimal approach remains controversial.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value p = 0.003
  • p-value p = 0.006
  • 95% CI 1.13-2.27
  • HR 1.60
  • 추적기간 5.1 years

이 논문을 인용하기

↓ .bib ↓ .ris
APA Yagi Y, Kanemasa Y, et al. (2025). Site- and Stage-Adapted Treatment Strategies for Gastrointestinal Diffuse Large B-Cell Lymphoma.. European journal of haematology, 115(3), 239-250. https://doi.org/10.1111/ejh.14440
MLA Yagi Y, et al.. "Site- and Stage-Adapted Treatment Strategies for Gastrointestinal Diffuse Large B-Cell Lymphoma.." European journal of haematology, vol. 115, no. 3, 2025, pp. 239-250.
PMID 40420508
DOI 10.1111/ejh.14440

Abstract

[OBJECTIVES] Although gastrointestinal diffuse large B-cell lymphoma (GI-DLBCL) is managed variously, the optimal approach remains controversial.

[METHODS] We retrospectively analyzed 701 patients with DLBCL at our institution between March 2004 and June 2024, including 160 with GI-DLBCL. We compared baseline characteristics and survival outcomes of GI-DLBCL with non-GI-DLBCL and further analyzed gastric and intestinal DLBCL by stage.

[RESULTS] No significant difference in survival outcomes was observed between GI and non-GI DLBCL groups after a median follow-up of 5.1 years. Among patients with gastric DLBCL, advanced disease was associated with poorer overall survival (OS) (hazard ratio [HR]: 1.75; 95% confidence interval [CI]: 1.18-2.58; p = 0.003) than localized disease. Similar findings were observed in intestinal DLBCL (HR: 1.60; 95% CI: 1.13-2.27; p = 0.006). Combined chemoradiation and chemotherapy yielded similar survival outcomes for localized gastric DLBCL although the former showed a higher cumulative incidence of secondary gastric cancer (p = 0.04). In localized intestinal DLBCL, multivariate analysis identified surgery followed by chemotherapy as a favorable prognostic factor for OS (HR: 0.23; 95% CI: 0.067-0.83; p = 0.024).

[CONCLUSIONS] Gastrointestinal diffuse large B-cell lymphoma had survival outcomes comparable to those of non-GI-DLBCL, suggesting site- and stage-specific therapies may confer a survival benefit.

MeSH Terms

Humans; Lymphoma, Large B-Cell, Diffuse; Male; Female; Middle Aged; Aged; Neoplasm Staging; Gastrointestinal Neoplasms; Retrospective Studies; Adult; Prognosis; Antineoplastic Combined Chemotherapy Protocols; Treatment Outcome; Aged, 80 and over; Combined Modality Therapy; Disease Management

같은 제1저자의 인용 많은 논문 (3)